Latest News

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 1st 2025

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo / image credit ©Tefi/stock.adobe.com
Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo

April 1st 2025

 Oral Semaglutide Lowers Risk of MACE 14% in Adults with T2D, ASCVD and/or CKD: Final Phase 3 SOUL Trial Readout/ image credit American College of Cardiology
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout

March 31st 2025

Women's  Heart Health News: 5 Studies from ACC.25 / image credit  ©Hamza/stock.adobe.com
Women's Heart Health: 5 Studies from ACC.25

March 28th 2025

Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose / image credit: ©New Africa/AdobeStock
Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose

March 27th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.